Education
Research Study: CBD for Dental Pain
May
This study delves into the efficacy and safety of cannabidiol (CBD) as an analgesic for acute dental pain, which is a significant health concern. The research, a randomized placebo-controlled clinical trial, involved 61 patients with moderate to severe toothache. These participants were divided into three groups: CBD10 (CBD 10 mg/kg), CBD20 (CBD 20 mg/kg), and a placebo group.
The primary outcome measured was the reduction in pain using a visual analog scale (VAS) from baseline within and among the groups. Secondary outcomes included changes in pain intensity, onset and duration of pain relief, changes in bite force, psychoactive effects, mood changes, and adverse events.
Both CBD groups showed significant reduction in pain compared to baseline and the placebo group.
CBD20 exhibited a faster onset of pain relief than CBD10, reaching maximum pain relief at 180 minutes after administration. The number needed to treat (NNT) was 3.1 for CBD10 and 2.4 for CBD20, indicating that a relatively small number of patients needed treatment to achieve significant pain relief.
Interestingly, both CBD groups also experienced a significant increase in bite force compared to baseline, suggesting an improvement in jaw function. However, CBD20 demonstrated a more pronounced increase in bite force compared to the placebo group.
In terms of safety, sedation, diarrhea, and abdominal pain were significantly associated with the CBD groups, but there were no significant psychoactive or mood change effects observed. Adverse events were generally mild and resolved within the observation period.
Overall, this study provides valuable clinical evidence supporting the effectiveness and safety of oral CBD as an analgesic for dental pain, offering a potential alternative to opioids for pain management in certain patient populations.
This study delves into the efficacy and safety of cannabidiol (CBD) as an analgesic for acute dental pain, which is a significant health concern. The research, a randomized placebo-controlled clinical trial, involved 61 patients with moderate to severe toothache. These participants were divided into three groups: CBD10 (CBD 10 mg/kg), CBD20 (CBD 20 mg/kg), and a placebo group.
The primary outcome measured was the reduction in pain using a visual analog scale (VAS) from baseline within and among the groups. Secondary outcomes included changes in pain intensity, onset and duration of pain relief, changes in bite force, psychoactive effects, mood changes, and adverse events.
Both CBD groups showed significant reduction in pain compared to baseline and the placebo group. CBD20 exhibited a faster onset of pain relief than CBD10, reaching maximum pain relief at 180 minutes after administration. The number needed to treat (NNT) was 3.1 for CBD10 and 2.4 for CBD20, indicating that a relatively small number of patients needed treatment to achieve significant pain relief.
Interestingly, both CBD groups also experienced a significant increase in bite force compared to baseline, suggesting an improvement in jaw function. However, CBD20 demonstrated a more pronounced increase in bite force compared to the placebo group.
In terms of safety, sedation, diarrhea, and abdominal pain were significantly associated with the CBD groups, but there were no significant psychoactive or mood change effects observed. Adverse events were generally mild and resolved within the observation period.
Overall, this study provides valuable clinical evidence supporting the effectiveness and safety of oral CBD as an analgesic for dental pain, offering a potential alternative to opioids for pain management in certain patient populations.
